Treatment horizon in multiple myeloma-Reference-Cited by-同舟云学术

Treatment horizon in multiple myeloma

Published:2022-09-18 Issue:5 Volume:109 Page:425-440
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Soekojo Cinnie Yentia¹²³^ORCID,Chng Wee Joo¹²³^ORCID

Affiliation:

1. Department of Hematology‐Oncology, National University Cancer Institute, Singapore National University Health System Singapore Singapore

2. Cancer Science Institute of Singapore National University of Singapore Singapore Singapore

3. N2CR and Department of Medicine Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore

Funder

Takeda Pharmaceuticals International

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13840

Reference133 articles.

1. Myeloma escape from immunity: an “inside” job

2. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline

3. Medical Scientific Advisory Group (MSAG) to Multiple Myeloma Australia (MFA).Clinical practice guideline multiple myeloma.2019. Accessed July 2020.https://myeloma.org.au/health-professional-resources/

4. Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets

5. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe;Patient Preference and Adherence;2024-09

2. Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma;Cancer Cell International;2024-08-05

3. AL amyloidosis manifesting as a vertebral amyloidoma secondary to an unrecognized plasmacytoma expressing cyclin D1 case report;International Journal of Surgery Case Reports;2024-08

4. Bone marrow fibrosis in newly diagnosed multiple myeloma and its correlation with clinicopathological factors;Diagnostic Pathology;2024-07-18

5. Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-06